4.7 Article

Therapeutic Strategies to Target the Androgen Receptor

期刊

JOURNAL OF MEDICINAL CHEMISTRY
卷 65, 期 13, 页码 8772-8797

出版社

AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.2c00716

关键词

-

资金

  1. Proteovant Therapeutics [P50 CA186786]
  2. National Cancer Institute, NIH [P30CA046592]
  3. University of Michigan Comprehensive Cancer Center Core Grant from the National Cancer Institute, NIH

向作者/读者索取更多资源

The androgen receptor (AR) is crucial in maintaining muscle and bone, supporting male sexual functions, and progressing prostate cancer. Various AR-targeted therapies have been developed, including AR agonists for bone loss and muscle atrophy, and AR antagonists for prostate cancer treatment.
The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual -related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target. Superscript/Subscript Available

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据